N/A N=23 Soft Tissue Mobilization Versus Therapeutic Ultrasound for Subjects With Neck and Arm Pain
Cervical Radiculopathy
Primary: Upper Limb Neurodynamic Tesnion (UNLT) Range of Motion — 4.60; 16.00 degrees
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Optical Measurements of the Skin Surface to Infer Distinctions in Myofascial Tissue Stiffness
Tissue Pain
Primary: Skin Stretch Response to Manual Lateral Pull — 0.512; 0.494; 0.508; 0.473 %/mm
N/A N=17 Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Traumatic Injury · Muscle Injury · Tendon Injury
Primary: Percent Change From Baseline in the Rectified and Integrated EMG Signal of the Tibialis Anterior Muscle At 24 Weeks Post-Operative — 1333 % change
N/A N=274 A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas.
Sarcoma
Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…
N/A N=42 Quantifying Myofascial Dysfunction in Post-Stroke Pain
Myofascial Dysfunction
Primary: T1 Rho MRI Relaxation Time of Shoulder External Rotator (Milliseconds) — 29.09; 27.15 milliseconds
N/A N=12 Repair of Soft Tissue Defect of the Finger Using the Heterodigital Neurocutaneous Island Flap
Sensory Reconstruction of the Volar Aspect of the Finger · The Heterodigital Neurocutaneous Island Flap
Primary: Discriminatory Sensation of the Flap — 8.3 mm
N/A N=183 Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
Phase 2 N=12 H-22411: BOTOX® for Peyronie's Disease
Peyronie's Disease
Primary: Average Percent Change of Penile Curvature in Degrees — -21.73; 2.429 percent change — p=0.5154
Phase 2 N=267 A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Malignant Rhabdoid Tumors (MRT) · Rhabdoid Tumors of the Kidney (RTK) · Atypical Teratoid Rhabdoid Tumors (ATRT)
Primary: Cohorts 1, 3, 4, 5, 6 and 7: Objective Response Rate (ORR) — 9.4; 9.4; 0.0; 16.1 Percentage of participants
N/A N=45 Scleroderma ARFI Imaging of the Skin
Scleroderma
Primary: Mean Skin Stiffness — 2.68; 2.07; 2.23; 2.27 meters per second — p=0.005
Phase 2 N=14 A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma
Lipoma
Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline
Phase 4 N=22 Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
Major Depressive Disorder · Soft Tissue Discomfort Syndrome · Pain
Primary: 24-hour Activity Level
N/A N=91 Flexion Versus Extension Soft Tissue Repair in Total Knee Arthroplasty
Total Knee Arthroplasty(TKA) · Total Knee Replacement
Primary: Knee Range of Motion (ROM) — 119; 120 degree
N/A N=24 To Compare Different Soft Tissue Grafts at the Time of Lateral Ridge Augmentation Procedure.
Bone Graft; Complications, Infection or Inflammation · Ridge Deficency · Dental Implant
Primary: Measure Changes Clinically in Crestal Soft Tissue Thickness (in mm) — 1.96; 1.59; 0.33 mm
Phase 3 N=221 An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Fibrodysplasia Ossificans Progressiva
Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)
Phase 2 N=48 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
N/A N=47 Evaluation of the Efficacy of the Use MD Tissue Collagen Medical Device in the Infiltrative Treatment of Greater Trochanter Pain Syndrome (GTPS)
Greater Trochanteric Pain Syndrome · GTPS - Greater Trochanteric Pain Syndrome · Tendon Disorder
Primary: Change in NRS (Numerical Rating Scale) Pain Score From Baseline (Week 0) to Week 10 — 4.7 NRS Pain Score (range 0-10; higher score
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
N/A N=35 Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
Soft Tissue Sarcoma
Primary: Local Disease Control Assessed by Physical Examination — 0 Participants
N/A N=24 Performance and Safety Evaluation of MD-Shoulder Collagen Medical Device in the Treatment of Rotator Cuff Syndrome
Rotator Cuff Tendinitis · Syndrome Rotator Cuff · Tendinopathy
Primary: Change From Baseline in Constant-Murley Score (CMS) at 3 Months — 10.03 units on a scale — p=0.001
Phase 2 N=19 Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma
Lipoma
Primary: Percent Change From Baseline in Surface Area of the Lipoma at Six Months — -81.277; 2.053 percentage change from baseline — p=<0.0001
N/A N=34 SERI® Surgical Scaffold for Soft Tissue Support in Revision Augmentation Surgery
Subjects Requiring Revision Breast Augmentation Surgery
Primary: Reoperation Rate (Per Implanted Breast) for the Presenting Condition at 12 Months. — 0; 0 Implanted breasts
Phase 3 N=35 Collagenase in the Treatment of Dupuytrens Disease
Dupuytren's Disease
Primary: Primary Outcome Measure is Reduction of Flexion Contracture of the Primary Joint. — 91.3; 0 % Joints
Phase 2 N=58 A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients
Phase 2 N=80 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
N/A N=420 Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections
Abscess
Primary: Sensitivity and Specificity of Bedside Emergency Ultrasound When Added to the Clinical Examination Compared With Clinical Examination Alone. — 94.7; 93.1; 84.2; 81.4…
N/A N=60 Evaluation of High-Purity Type I Collagen Biologic Wrap to Improve Function After Extensor Tendon Repair of the Hand
Injury of Extensor Tendon of Hand · Tendon Adhesions
Primary: Total Active Motion (TAM) of Involved Finger(s) — 232.4; 201.3 degrees
Phase 2 N=73 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months